Search

Your search keyword '"Lars Henrik Jensen"' showing total 181 results

Search Constraints

Start Over You searched for: Author "Lars Henrik Jensen" Remove constraint Author: "Lars Henrik Jensen"
181 results on '"Lars Henrik Jensen"'

Search Results

1. Identification of patients’ smoking status using an explainable AI approach: a Danish electronic health records case study

2. Missingness mechanisms and generalizability of patient reported outcome measures in colorectal cancer survivors – assessing the reasonableness of the 'missing completely at random' assumption

3. Electron beam radiotherapy for the management of squamous cell carcinoma of the anal margin

4. Lung cancer among outpatients with COPD: a 7-year cohort study

5. Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study

6. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

7. Single-cell and bulk RNA sequencing reveal ligands and receptors associated with worse overall survival in serous ovarian cancer

8. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer

10. Efficacy of open dialogue about complementary and alternative medicine compared with standard care in improving quality of life in patients undergoing conventional oncology treatment (CAMONCO 2): protocol for a randomised controlled trial

11. The Clinical Impact of MicroRNA-21 in Low Rectal Cancer Treated with High-Dose Chemoradiotherapy in the Organ Preserving Setting

12. Study protocol: a randomized controlled trial comparing the efficacy of therapist guided internet-delivered cognitive therapy (TG-iConquerFear) with augmented treatment as usual in reducing fear of cancer recurrence in Danish colorectal cancer survivors

13. Study protocol designed to investigate tumour response to calcium electroporation in cancers affecting the skin: a non-randomised phase II clinical trial

14. Re‐exposure to immunotherapy in metastatic colon cancer: A case report

15. Radiotherapy for metastatic spinal cord compression with increased radiation doses (RAMSES-01): a prospective multicenter study

16. Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report

17. Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer

18. Improving continuity by bringing the cancer patient, general practitioner and oncologist together in a shared video-based consultation – protocol for a randomised controlled trial

19. Cross-sectoral communication by bringing together patient with cancer, general practitioner and oncologist in a video-based consultation: a qualitative study of oncologists’ and nurse specialists’ perspectives

20. Cross-sectoral video consultation in cancer care: GPs’ evaluation of a randomised controlled trial

21. Investigating whether shared video-based consultations with patients, oncologists, and GPs can benefit patient-centred cancer care: a qualitative study

22. Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials

24. Protein Signatures and Individual Circulating Proteins, including IL-6 and IL-15, Associated with Prognosis in Patients with Biliary Tract Cancer

25. Open dialogue about complementary and alternative medicine early in the oncology treatment trajectory:A qualitative study of patients’ lived experiences

26. The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab

27. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177):final analysis of a randomised, open-label, phase 3 study

28. Efficacy of open dialogue about complementary and alternative medicine compared with standard care in improving quality of life in patients undergoing conventional oncology treatment (CAMONCO 2):protocol for a randomised controlled trial

29. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

30. Open dialogue about complementary and alternative medicine (CAM) integrated in conventional oncology care, characteristics and impact. A systematic review

31. Impact of Open Dialogue about Complementary Alternative Medicine—A Phase II Randomized Controlled Trial

32. Delta Tocotrienol as a Supplement to FOLFOXIRI in First Line Treatment of Metastatic Colorectal Cancer. A Randomized, Double-blind, Placebo-controlled Phase II Study

33. OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol

34. The 'Immunoscore' in rectal cancer:could we search quality beyond quantity of life?

36. NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer

37. Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations

38. Study protocol designed to investigate tumour response to calcium electroporation in cancers affecting the skin:a non-randomised phase II clinical trial

39. Re‐exposure to immunotherapy in metastatic colon cancer: A case report

40. Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report

41. A new model of early, integrated palliative care: palliative rehabilitation for newly diagnosed patients with non-resectable cancer

43. Curative chemoradiation for low rectal cancer: Primary clinical outcomes from a multicenter phase II trial

44. Functional precision medicine in colorectal cancer based on patient-derived tumoroids and in-vitro sensitivity drug testing

45. Early, integrated palliative rehabilitation improves quality of life of patients with newly diagnosed advanced cancer: The Pal-Rehab randomized controlled trial

46. Impact of integrative open dialogue about complementary alternative medicine. A phase II randomized controlled trial

47. Cross-sectoral communication by bringing together patient with cancer, general practitioner and oncologist in a video-based consultation:a qualitative study of oncologists' and nurse specialists' perspectives

48. Early ctDNA response to chemotherapy:A potential surrogate marker for overall survival

49. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177):an open-label, randomised, phase 3 trial

50. Cross-sectoral video consultation in cancer care: GPs’ evaluation of a randomised controlled trial

Catalog

Books, media, physical & digital resources